Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484185 | 0.91 | MAPT (0.68) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL9568616 | 0.90 | MAPT (0.66) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL9632939 | 0.88 | MCHR1 (0.67) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL18691791 | 0.88 | MCHR1 (0.67) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL16114005 | 0.88 | MCHR1 (0.67) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL10647335 | 0.88 | MCHR1 (0.67) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL19733315 | 0.87 | MCHR1 (0.57) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL1101347 | 0.85 | MAPT (0.68) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL1101341 | 0.84 | MAPT (0.69) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL6031547 | 0.84 | KDM4E (0.79) | MAPTRAB9AKDM4ELMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5482938-A | Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | claimed |
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| WO-2006057503-A1 | NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES, LTD. (KR) | 2006-06-01 | — | — | WO | disclosed |
| EP-0975586-A2 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | Sumitomo Chemical Company, Limited (JP) | 2000-02-02 | — | — | EP | disclosed |
| EP-0968198-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING $g(b)-AMYLOID PEPTIDE | Elan Pharmaceuticals, Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998045254-A2 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998038177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE | ELAN PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | MAPT 2869/4885RAB9A 2802/4885KDM4E 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.